Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021
Virpax Pharmaceuticals, Inc. (VRPX)
Company Research
Source: Business Wire
--Company’s Enkephalin Product under Development-- BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced it will present a poster on Leucine Enkephalin as a potential analgesic at PAINWeek 2021, being held on September 7-11, 2021 at The Cosmopolitan in Las Vegas, NV.The following poster from Virpax will be presented on Thursday, September 9th from 6:30 p.m. – 8:30 p.m. PST:Title: Enkephalin as a Potential Analgesic and CNS ModulatorPresenter: Jeffrey A. Gudin, MD, EVP, Chief Medical Officer of Virpax PharmaceuticalsAbstract ID: 1090715 Poster No.: 29For further information, please visit https://www.painweek.org/“Drug overdose deaths in the U.S. rose nearly 30% in 2020. The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is supporting scientific solutions to stem the national opioid public health crisis,” stated Jeffrey Gudin, MD, co-founder and EVP, Chief Medical Officer of Virpax. “Our research
Show less
Read more
Impact Snapshot
Event Time:
VRPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRPX alerts
High impacting Virpax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
VRPX
News
- Virpax Pharmaceuticals Reports 2023 Year-End Results [Yahoo! Finance]Yahoo! Finance
- Virpax Pharmaceuticals Reports 2023 Year-End ResultsBusiness Wire
- Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of SAcquire Media Monitor
- Scilex and Sorrento settle with Virpax and its founder Anthony Mack [Seeking Alpha]Seeking Alpha
- Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price [Yahoo! Finance]Yahoo! Finance
VRPX
Sec Filings
- 4/18/24 - Form S-1
- 4/5/24 - Form S-8
- 4/3/24 - Form 8-K
- VRPX's page on the SEC website